NCT01965613View on ClinicalTrials.gov

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Pyoderma Gangrenosum
Interventions
BIOLOGICAL

Xilonix

IV

Trial Locations (1)

32308

XBiotech Investigative Site, Tallahassee

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01965613 - A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum | Biotech Hunter | Biotech Hunter